LXRX News & Events

Lexicon Pharmaceuticals announced that results from its Progress Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain, DPNP, supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development will be presented on Wednesday April 22, during the American Academy of Neurology, AAN, Annual Meeting. At the meeting, the company will also present results of an evaluation of pilavapadin on spasticity-related endpoints in preclinical models of multiple sclerosis and spinal cord injury. The congress is being held April 18-22 in Chicago, Illinois. In a session titled "Additional Efficacy Data Support Selection of Pilavapadin 10 mg for Phase 3 Development in DPNP: Results From PROGRESS," the company will present data from the study on pain outcomes as measured by the Brief Pain Inventory-Diabetic Peripheral Neuropathy patient reported instrument. Pilavapadin 10 mg achieved a nominally significant reduction in Average Pain at Week 8 versus placebo, with concordant improvements in Worst and Least Daily Pain, as measured by BPI-DPN. The 10 mg dose was generally well-tolerated over 8 weeks, with completion rates comparable to placebo and few discontinuations due to treatment emergent adverse events. Overall, these results provide additional support for the advancement of pilavapadin 10 mg into Phase 3 evaluation in DPNP.

Rick Sowers, President and CEO of the Company and the Bank stated, "The first quarter showed seasonally strong core deposit growth as a result of onboarding new profitable Client Relationships which continues to be our primary objective. This growth is supported by an outstanding Team of professionals who provide our Clients with exceptional service. Our net income, return on assets, return on equity and SBA gain on sale were up over the prior quarter as we focused on expense management amid tepid loan growth and an increasingly competitive credit market. Our discipline on pricing both in lending and deposits resulted in core NIM expansion."

Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candidate. In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon has earned a second $10M milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the Phase 1 study and is eligible for a third $10M milestone payment that may be achieved later this year. In total, Lexicon is eligible to receive up to $1B in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.

Lexicon Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes. The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-designed trials in patients with type 1 diabetes and were encouraged to find that treatment with sotagliflozin resulted in improvements in multiple efficacy measures after one year in both those with normal kidney function and those with mildly reduced kidney function," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "Not only was sotagliflozin shown to improve cardiometabolic parameters in this patient population, but it also reduced clinically important hypoglycemia events, which are a leading cause of acute mortality and morbidity and can be life-threatening." Lexicon remains on track to resubmit the New Drug Application for ZYNQUISTA glycemic control in patients with type 1 diabetes in 2026 based upon U.S. Food and Drug Administration feedback and additional clinical data received to date from the STENO1 study